In view of the established exposure–toxicity relationships for many TKIs, the observations made here further suggest that OATP1B1-mediated transport, which occurs in advance of hepatic metabolism, may contribute to interindividual pharmacokinetic variability observed previously in patients with cancer requiring treatment with TKIs. The gene discussed is SLCO1B1; the disease is cancer.